# Idiopathic Pulmonary Fibrosis (IPF) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis-ipf

> 10 upcoming FDA catalysts in idiopathic Pulmonary Fibrosis (IPF): AP02 (AVLN) on December 2026 (primary completion); AP02 (AVLN) on Dec 2026 to Mar 2027 (topline data readout); buloxibutid (VCRE) on May 2027 (primary completion); buloxibutid (VCRE) on May to Aug 2027 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2026 | [AP02 primary completion](https://sec-api.dev/pdufa/ap02) | AVLN | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07194382 (AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Avalyn Pharma Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07194382)) |
| Dec 2026 to Mar 2027 | [AP02 topline data readout](https://sec-api.dev/pdufa/ap02) | AVLN | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07194382 (AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Avalyn Pharma Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07194382)) |
| May 2027 | [Buloxibutid primary completion](https://sec-api.dev/pdufa/buloxibutid) | VCRE | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT06588686 (A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Vicore Pharma AB." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588686)) |
| May to Aug 2027 | [Buloxibutid topline data readout](https://sec-api.dev/pdufa/buloxibutid) | VCRE | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT06588686 (A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Vicore Pharma AB." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588686)) |
| Sep to Dec 2027 | [LTI-03 topline data readout](https://sec-api.dev/pdufa/lti-03) | RNTX | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT06968845 (A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Rein Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06968845)) |
| September 2027 | [LTI-03 primary completion](https://sec-api.dev/pdufa/lti-03) | RNTX | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT06968845 (A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Rein Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06968845)) |
| Sep to Dec 2028 | [Azd8965 low dose topline data readout](https://sec-api.dev/pdufa/azd8965) | AZN | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07652658 (A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07652658)) |
| September 2028 | [Azd8965 low dose primary completion](https://sec-api.dev/pdufa/azd8965) | AZN | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07652658 (A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07652658)) |
| November 2029 | [Deupirfenidone primary completion](https://sec-api.dev/pdufa/deupirfenidone) | PTCHF | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07284602 (Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor PureTech." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284602)) |
| Nov 2029 to Feb 2030 | [Deupirfenidone topline data readout](https://sec-api.dev/pdufa/deupirfenidone) | PTCHF | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07284602 (Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor PureTech." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284602)) |

## Drugs

- [AP02](https://sec-api.dev/pdufa/ap02) (AVLN)
- [Buloxibutid](https://sec-api.dev/pdufa/buloxibutid) (VCRE)
- [LTI-03](https://sec-api.dev/pdufa/lti-03) (RNTX)
- [Azd8965 low dose](https://sec-api.dev/pdufa/azd8965) (AZN)
- [Deupirfenidone](https://sec-api.dev/pdufa/deupirfenidone) (PTCHF)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis-ipf.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Idiopathic Pulmonary Fibrosis (IPF) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis-ipf

```bibtex
@misc{secapidev_indications_idiopathic_pulmonary_fibrosis_ipf_20261116,
  title        = {Idiopathic Pulmonary Fibrosis (IPF) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis-ipf}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_idiopathic_pulmonary_fibrosis_ipf_20261116","title":"Idiopathic Pulmonary Fibrosis (IPF) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis-ipf","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
